Podcasts about disparities

Host Davide Soldato and guest Dr. John K. Lin discuss the JCO article "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-For-Service Beneficiaries with Metastatic Breast, Colorectal, Lung, and Prostate Cancer." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we sit down with authors of the latest articles published in the Journal of Clinical Oncology. I'm your host, Dr. Davide Soldato, a medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by Dr. Lin, assistant professor in the Department of Health Services Research at the University of Texas MD Anderson Cancer Center. Dr. Lin and I will be discussing the article titled, "Racial and Ethnic Disparities Along the Treatment Cascade Among  Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." Thank you for speaking with us, Dr. Lin. Dr. Lin: Thank you so much for having me. I appreciate it. Dr. Davide Soldato: So, just to start, to frame a little bit the study, I just wanted to ask you what prompted you and your team to look specifically at this question - so, racial and ethnic disparities within this specific population? And related to this question, I just wanted to ask how this work is different or builds on previous work that has been done on this research topic. Dr. Lin: Yeah, absolutely. Part of the impetus for this study was the observation that despite people who are black or Hispanic having equivalent health insurance status - they all have  Medicare Fee-for-Service - we've known that treatment and survival differences and disparities have persisted over time for patients with metastatic breast, colorectal, lung, and prostate cancer. And so, the question that we had was, "Why is this happening, and what can we do about it?" One of the reasons why eliminating racial and ethnic disparities in survival among Medicare beneficiaries with metastatic cancer has been elusive is because these disparities are occurring along a lot of dimensions. Whether or not it's because the patient presented late and has very extensive metastatic cancer; whether or not the patient has had a difficult time even seeing an oncologist; whether or not the patient has had a difficult time starting on any systemic therapy; or maybe it's because the patient has had a difficult time getting guideline-concordant systemic therapy because, more recently, these treatments have become so expensive. Disparities, we know, are occurring along all of these different facets and areas of the treatment cascade. Understanding which one of these is the most important is the key to helping us alleviate these disparities. And so, one of our goals was to evaluate disparities along the entire treatment cascade to try to identify which disparities are most important. Dr. Davide Soldato: Thank you very much. That was very clear. So, basically, one of the most important parts of the research that you have performed is really focusing on the entire treatment cascade. So, basically, starting from the moment of diagnosis up to the moment where there was the first line of treatment, if this line of treatment was given to the patient. So, I was wondering a little bit, because for this type of analysis, you used the SEER-Medicare linked database. So, can you tell us a little bit which was the period of time that you selected for the analysis? Why do you think that that was the most appropriate time to look at this specific question? And whether you feel like there is any potential limitation in using this type of database and how you handled this type of limitations? Dr. Lin: Yeah, absolutely. It's a great question. And I want to back up a little bit because I want to talk about the entire treatment cascade because I think that this is really important for our research and for future research. We weren't the first people to look at along the treatment cascade for a disease. Actually, this idea of looking along the treatment cascade was pioneered by HIV researchers and has been used for over a decade by people who study HIV. And there are a lot of parallels between HIV and cancer. One of them is that with HIV, there are so many areas along that entire treatment cascade that have to go right for somebody's treatment to go well. Patients have to be diagnosed early, they have to be given the right type of antiretrovirals, they have to be adherent to those antiretrovirals. And if you have a breakdown in any one of those areas, you're going to have disparities in care for these HIV patients. And so, HIV researchers have known this for a long time, and this has been a big cornerstone in the success of getting people with HIV the treatment that they need. And I think that this has a lot of parallels with cancer as well. And so, I am hoping that this study can serve as a model for future research to look along the entire treatment cascade for cancer because cancer is, similarly, one of these areas that requires multidisciplinary, complex medical care. And understanding where it is breaking down, I think, is crucial to us figuring out how we can reduce disparities. But for your question about the SEER-Medicare linked database, so we looked between 2016 and 2019. That was the most recent data that was available to us. And one of the reasons why we were excited to look at this is because there were some new treatments that were just released and FDA-approved around 2018, which we were able to study. And this included immunotherapy for non–small cell lung cancer, and then it also included androgen receptor pathway inhibitors, the second-generation ones, for prostate cancer. And the reason why this is important is because for some time, as we have developed these new therapies, there's been a lot of concern that there have been disparities in access to these novel therapies because of how expensive they are, particularly for the Medicare population. And so one of the reasons why we looked specifically at this time period was to understand whether or not, in more recent years, these novel therapies, people are having increasing disparities in them and whether or not increasing disparities in these more expensive, newer therapies is contributing to disparities in mortality. That being said, obviously, we're in 2025 and these data are by now six years old, and so there are additional therapies that are now available that weren't available in the past. But I think that, that being said, at least it's sort of a starting point for some of the more important therapies that have been introduced, at least for non–small cell lung cancer and prostate cancer. And the database, SEER-Medicare, is helpful because it uses the population cancer registry, which is the SEER registry cancer registry, linked to Medicare claims. So, any type of medical care that's billed through Medicare, which is going to basically be all of the medical care that these patients receive, for the most part, we're going to be able to see it. And so, I think that this is a really powerful database which has been used in a lot of research to understand what kind of care is being received that has been billed through Medicare. So, one of the limitations with this database is if there is care that's received that was not billed through Medicare, we're not going to be able to see that. And this does not happen probably that frequently, particularly because most patients who have insurance are going to be receiving care through insurance. However, we may see it for some of the oral Part D drugs. Some of those drugs are so expensive that patients cannot pay for the coinsurance during that time. And it's possible that some of those drugs patients were getting for free through the manufacturer. We potentially missed some of that. Dr. Davide Soldato: So, going a little bit into the results, I think that these are very, very interesting. And probably the most striking one is that when we look at the receipt of any type of treatment for metastatic breast, colorectal, prostate, and lung cancer - and specifically when we look at guideline-directed first-line treatments - you observed striking differences. So, I just wanted you to guide us a little bit through the results and tell us a little bit which of the numbers surprised you the most. Dr. Lin: So, what we were expecting is to see large disparities in receiving what we called guideline-directed systemic therapy. And guideline-directed systemic therapy during this time kind of depended on the cancer. So, we thought that we were going to see large disparities in guideline-directed therapy because these were the more novel therapies that were approved, and thus they were going to be the more expensive therapies. And so, what this meant was for colorectal cancer, this was going to be any 5-FU–based therapy. For lung cancer, this was going to be any checkpoint inhibitor–based therapy. For prostate cancer, this was going to be any ARPI, so this was going to be things like abiraterone or enzalutamide. And for breast cancer, this was going to be CDK4 and 6 TKIs plus any aromatase inhibitor. And so, for instance, for breast, prostate, and lung cancer, these were going to be including more expensive therapies. And so, what we expected to see was large disparities in receiving some of these more expensive, novel therapies. And we thought we were going to see fewer disparities in receiving some of the cheaper therapies, such as aromatase inhibitors, 5-FU, older platinum chemotherapies for lung cancer, and ADT for prostate cancer. We were shocked to find that we saw large racial and ethnic disparities in seeing some of the older, cheaper chemotherapies and hormonal therapies. So for instance, for breast cancer, 59% of black patients received systemic therapy, whereas 68% of white patients received systemic therapy. For colorectal, only 23% of black patients received any systemic therapy versus 34% of white patients. For lung, only 26% of black patients received any therapy, whereas 39% of white patients did. And for prostate, only 56% of black patients received any systemic therapy versus 77% of white patients. And so, we were pretty shocked by how large the disparities were in receiving these cheap, easy-to-access systemic therapies. Dr. Davide Soldato: Thank you very much. So, I just wanted to go a little bit deeper in the results because, as you said, there were striking differences even when we looked at very old and also cheap treatments that, for the majority of the patients that were included inside of your study, were actually basically available for a very small price to these patients who had the eligibility for Medicare or Medicaid. And I think that one of the very interesting parts of the research was actually the attention that you had at looking how much of these disparities could be explained by several factors. And actually, one of the most interesting results is that you observed that low-income subsidy status was actually a big determinant of these disparities in terms of treatment. So, I just wanted to guide us a little bit through these results and then just your opinion about how these results should be interpreted by policymakers. Dr. Lin: Yeah, absolutely. I'm going to explain a little bit about what low-income subsidy status is and dual-eligibility status. Some of the listeners may not know what low-income subsidy status or dual-eligibility status is. Low-income subsidy status is part of Medicare Part D. Medicare Part D is an insurance benefit that allows patients to receive oral drugs. So these are drugs that are dispensed through the pharmacy, such as the CDK4/6 inhibitors, as well as second-generation ARPIs in our study. For patients who have Medicare Part D and whose income is low enough - falls below a certain federal poverty level threshold - those patients will receive their oral drugs for much cheaper. And this is really important for some of these more novel therapies because for some of these more novel therapies, if you don't have low-income subsidy status, you may be paying thousands of dollars for a single prescription of those drugs. Whereas if you have low-income subsidy status, you may be paying less than $10. And so that difference, greater than $1,000 or $2,000 versus less than $10, one would think that the patient who's paying less than $10 would be much more likely to receive those therapies. So that's low-income subsidy status. Low-income subsidy status, importantly, doesn't apply for infused medications like immunotherapy. But it's important to know that most people with low-income subsidy status - about 88% - are also dual-eligible. What dual-eligible means is that they have both Medicare and Medicaid. Medicare being the insurance that everybody has in our study who's greater than 65. And Medicaid is the state-run but federally subsidized insurance that patients with low incomes have. And so patients who are dual-eligible - and about 87% of those with low-income subsidy status are dual-eligible - those patients have both Medicaid and Medicare, and they basically pay next to nothing for any of their medical care. And that's because Medicare will reimburse most of the medical care and the copays or coinsurance are going to be covered by Medicaid. So Medicaid is going to pick up the rest of the bill. So, most of the patients who have low-income subsidy status who are dual-eligible, these patients pay almost nothing for their medical care - Part B or Part D, any of their drugs. And so, one would expect that if cost were the main determinant of disparities in cancer care, then one would expect that dual-eligibles, most of them would be receiving treatment because they're facing minimal to no costs. What we found is that when we broke down the racial and ethnic disparity by a number of factors - including LIS status/dual eligibility, age, the number of comorbidities, etcetera - what we found was that the LIS or dual-eligibility status explained about 20% to 45% of the disparities that we saw in receiving treatment. And what that means is despite these patients paying next to nothing for their drugs, these are the most likely patients to not be treated for their cancer at all. So they're most likely to basically be diagnosed, survive for two months, see an oncologist, and then never receive any systemic therapy for their cancer. And this is not just chemotherapies for colorectal or lung cancer. This includes cheaper, easier-to-tolerate hormonal therapies that you can just take at home for breast cancer, or you can get every six months for prostate cancer, that people who even have poorer functional status are able to take. However, for whatever reason, these dual-eligible or LIS patients are very unlikely to receive treatment compared to any other patient. The low likelihood of treating this group of patients, that explains a large portion of the racial and ethnic disparities that we see. Dr. Davide Soldato: And one thing that I think is very interesting and might be of potential interest to our listeners is, did you compare survival outcomes in these different settings? And did you observe any significant differences in terms of racial and ethnic disparities once you saw that there was a significant difference when looking at both receipt of any type of treatment and also guideline-directed treatments? Dr. Lin: We saw that there were large disparities in survival by race and ethnicity when you look overall. However, when you just account for the patients who received any systemic therapy at all - not just guideline-directed systemic therapy - those differences in survival essentially disappeared. And so, what that suggests is that if black patients were just as likely to receive any systemic therapy at all as white patients, we would expect that the survival differences that we were seeing would disappear. And this is not even just looking at guideline-directed systemic therapy. This was looking just at systemic therapy alone. And so, while guideline-directed systemic therapy should be a goal, our research suggests that if we are to close the gap in disparities in overall survival among black and white patients, we must first focus on patients just receiving any type of treatment at all. And that should be the very first focus that policymakers, that leaders in ASCO, that health system leaders, that physicians, that we should focus on: just trying to get any type of treatment to our patients who are poorer or black. Dr. Davide Soldato: Thank you very much. And this was not directly related to the research that you performed, but going back to this very point - so, increasing the number of patients that receive any kind of systemic treatment before looking at guideline-directed treatments - what would you feel would be the best way to approach this in order to decrease the disparities? Would you look at interventions such as financial navigation or maybe improving referral pathways or providing maybe more culturally adapted information to the patients? Because in the end, what we see is disparities based on racial and ethnicity. We see that we can reduce these disparities if we get these patients to the treatment. But in the end, what would you feel is the best way to bring patients to these types of treatments? Dr. Lin: I think the most important thing is to understand that these disparities are not primarily happening because of the high cost of cancer treatment. These disparities are happening because of other social vulnerabilities that these patients are facing. And so these vulnerabilities could be a lot of things. It could be mistrust of the medical system. It could be fear of chemotherapy or other treatments. It could be difficulty taking time off of work. It could be any number of things. What we do know is when we've looked at the types of interventions that can help patients receive treatment, navigation is probably the most effective one. And the reason why I think that is because when patients don't receive treatment because of social vulnerability, I sort of look at social vulnerability like links in a chain. Any weakest link is going to result in the patient not receiving treatment. This may be because they have a hard time taking time off of work. This may be because they had a hard time getting transportation to their physician. It may be because they had an interaction with a physician, but that interaction was challenging for the patient. Maybe they mistrusted the physician. Maybe they're worried about the medical system. If any of these things goes wrong, the patient is not going to be treated. The patient navigator is the only person who can spot any of those weak links within the chain and address them. And so, I think that the first thing to do is to get patient navigation systems in place for our vulnerable patients throughout the United States. And this is incredibly important because in Medicare, patient navigation is reimbursable. And so this is not something that's ‘pie in the sky'. This is something that's achievable today. The second thing is that it's really important that we see these vulnerabilities happening for patients who are dual-eligible, who have both Medicare and Medicaid. One of the reasons why this is important is because there has been a lot of research outside of what we've done that has shown vulnerabilities for dual-eligible patients who have Medicare for a number of different diseases. And the reason why is because, although patients are supposed to have the benefits of both Medicare and Medicaid, usually these two insurances do not play nicely together. It creates a huge, bureaucratic, complex mess and maze that most of these patients are unable to navigate. And so many of these patients are unable to actually receive the full reimbursement from both Medicare and Medicaid that they should be getting because those two insurers are not communicating well. And so the second thing is that national cancer organizations need to be supporting policies and legislation that is already being discussed in Congress to revamp the dual-eligible system so that it facilitates these patients getting properly reimbursed for their care from both Medicare and Medicaid and these systems working together well. The third thing is that Medicaid itself has many benefits that can allow patients to receive care, like they have transportation benefits so that patients can get to and from their doctor's appointments with ease. And so I think this will be additionally very, very helpful for patients. The last thing is, you know, it's possible that future innovations such as telemedicine and tele-oncology and cancer care at home can also make it easier for some of these patients who may be working a lot to receive care. But what I would say is that our study should be a call for healthcare delivery researchers to start piloting interventions to be able to help these patients receive systemic therapy. And so what this could look like is trying to get that care navigation and implement that in clinics so that patients can be receiving the care that they need. Dr. Davide Soldato: Thank you very much. That was a very clear perspective on how we can tackle this issue. So, I just wanted to close with a sort of personal question. I was wondering what led you to work specifically in this research field that is very challenging, but I think it's particularly critical in healthcare systems like in the United States. Dr. Lin: Yeah, absolutely. One of the most important things for me as an oncologist and a researcher is being able to know that all patients in the United States - and obviously abroad - who have cancer should be able to receive the kind of care that they deserve. I don't think that patients, because their incomes are lower or because their skin looks a certain color or because they live in rural areas, these shouldn't be determinants of whether or not cancer patients are receiving the care that they need. We can develop and pioneer the very best treatments and breakthroughs in oncology, but if our patients are not receiving them - if only 20% of our patients with colon cancer or lung cancer are receiving any type of systemic therapy, who are black - this is a big problem. But this is something that I think that our system can tackle. We need to get these breakthroughs that we have in oncology to every single cancer patient in America and every single cancer patient in the world. I think this is a goal that all oncologists should have, and I think that this is something that, honestly, is achievable. I think that research is a powerful tool to give us a lens into understanding exactly why it is that certain patients are not getting the care that they deserve. And my goal is to continue to use research to shed light on why our system is not performing the way that we all want it to be. Dr. Davide Soldato: Circling back to your research, actually the manuscript that was published was supported by a Young Investigator Award by the American Society of Clinical Oncology. So, was this the first step of a more broad research, or do you have any further plans to go deeper in this topic? Dr. Lin: Yeah, absolutely. First, I want to thank the ASCO Young Investigator Award for funding this research because I think it's fair to say that this research would not have happened at all without the support of the ASCO YIA. And the fact that ASCO is doing as much as it can to support the future generation of cancer researchers is incredible. And it's a huge resource, and having it come at the time that it did is critical for so many of us. So I think that this is an unbelievable thing that ASCO does and continues to do with all of its partners. For me, yeah, this is definitely a stepping stone to further research.  Medicare Fee-for-Service is only one part of the population. I want to spread this research and extend it to patients who have other types of insurances, look at other types of policies, and also try to conduct some of the cancer care delivery research that's needed to try to pilot some interventions that can resolve this problem. So hopefully this is the first step in a broader series of studies that we can all do collectively to try to eliminate racial and ethnic disparities in cancer care and survival. Dr. Davide Soldato: So, I think that we've come at the end of this podcast. Thank you again, Dr. Lin, for joining us today. Dr. Lin: Thank you so much. It was a pleasure to be a part of this. Dr. Davide Soldato: So, we appreciate you sharing more on your JCO article, "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Last Chance: Multiple Myeloma Task Force Podcast Don't miss your final opportunity to listen to this CME/NCPD-accredited podcast on Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Healthcare Disparities in Relapsed/Refractory Multiple Myeloma. Last chance to listen and claim credit is September 10, 2025. Hear from Task Force Co-Chairs Dr. Sikander Ailawadhi (Mayo Clinic) and Dr. Rahul Banerjee (Fred Hutchinson Cancer Center/University of Washington) as they discuss strategies for improving patient outcomes and addressing healthcare disparities in relapsed/refractory multiple myeloma. Click here to claim your CME/NCPD credit: https://bit.ly/4e25pQP

Navigating workplace pay transparency reveals deeper issues with corporate compensation structures that value years of experience over actual performance and results.• Pay transparency can create uncomfortable situations when high performers discover they're paid similarly to underperforming team members• Experience-based pay scales often fail to reward actual contribution and value• Out-of-band pay adjustments may be necessary when structural inequities threaten to drive away top performers• Performance-based compensation models with significant bonus components create healthier incentive structures• Managers must be judicious when making offers to ensure pay reflects value, not just years of experience• Calibrating pay across teams helps identify and address potential equity issues before they become problems• Young, high-performing employees are often at a disadvantage in negotiating their true worthJoin our Discord community to participate in our new game "Is it AI?" where you can test whether you can still identify AI-generated images, plus access exclusive content and conversations.Click/Tap HERE for everything Corporate StrategyElevator Music by Julian Avila Promoted by MrSnoozeDon't forget ⭐⭐⭐⭐⭐ it helps!

Food insecurity is a systemic public health issue that needs to be addressed because reliable access to healthy food is critical to positive health outcomes. Health care partnerships are forming to improve access to healthy foods in some states, including Massachusetts, which is at the forefront of addressing food insecurity with programs that allow Medicaid funding to be used to address social determinants of health. “I would push back on the idea that things like food and housing are not actually medical,” says Jennifer Obadia, senior director of health care partnerships at Project Bread, a nonprofit focused on creating a sustainable, system-wide safety net in Massachusetts for anyone facing hunger.  “Now, I understand they're not pharmaceutical,” she adds. “But we know that 80% of a person's health is determined by social and environmental factors.” In this week's episode, Jennifer Obadia speaks with Movement Is Life's Sonia Cervantes about food insecurity, Project Bread's mission, lessons learned over the years and shares a call to action for listeners. Project Bread's FoodSource Hotline (1-800-645-8333) is the food assistance line for all of Massachusetts, whether you need help paying for food and don't know where to start or you're simply curious about ways to boost your food budget or save on groceries.   Never miss an episode – be sure to subscribe to The Health Disparities podcast from Movement Is Life on Apple Podcasts, YouTube, or wherever you get your podcasts.

Explore the clash between Christianity and socialism featuring theologian, Dr. Thaddeus Williams (CFBU board member and Biola professor). Is Christian socialism biblical? He unpacks the biblical implications, exposing incongruences between socialism and historic Christian faith. Don't miss this deep dive into faith, economics, and biblical truth! This is part 1 of two conversations we will be having with Dr. Williams on this topic. Watch the debate between Thaddeus Williams & Malcolm Foley: https://www.youtube.com/watch?v=WN0giB3lvmU Resources referenced or recommended in this video include: The Poverty Cure series by the Acton Institute: • Poverty Cure | Series Social Justice by Cal Beisner: https://downloads.frc.org/EF/EF13E133... Social Justice and the Christian Church by Ronald Nash: https://www.amazon.com/Social-Justice... Confronting Injustice without Compromising Truth by Thaddeus Williams: https://www.amazon.com/Confronting-In... The Anti-Greed Gospel by Malcom Foley: https://www.amazon.com/Anti-Greed-Gos... The Black Book of Communism: https://www.amazon.com/Black-Book-Com... Black Rednecks and White Liberals by Thomas Sowell https://www.amazon.com/Black-Rednecks... Discrimination and Disparities by Thomas Sowell: https://www.amazon.com/Discrimination... “Avarice, Prudence, and the Bourgeois Virtues” by Deirdre McCloskey https://www.deirdremccloskey.com/docs... If the content of Dr. Thaddeus Williams' Shed & Beam brightens your day please take a second to like, subscribe, and share with friends. Cheers!

Conversation is an important part of bringing an end to racism so that everyone thrives in our society. It's something that the leaders of 904Ward care deeply about.  The 904Ward organization evolved the Jacksonville 904 dialing area code into a nonprofit whose mission is to create racial healing and equity through deep conversations and learning, trusting relationships, and collective action.  Dr. Kimberly Allen served as the inaugural CEO of 904WARD from 2020 to 2025.  “I think we all make judgments all the time because that's just the nature of our brains and how it works, but what I would encourage us to do is to call those judgments out and, I say, ‘Say the quiet part out loud.' Call those judgments  out so that you can start to work through where they come from,” Dr. Allen says.  In this conversation, which was first recorded in 2022 for the Health Disparities podcast, Dr. Allen is joined by 904 resident Sharon LaSure-Roy. They spoke with Movement Is Life's Sarah Hohman. Never miss an episode – be sure to subscribe to The Health Disparities podcast from Movement Is Life on Apple Podcasts, YouTube, or wherever you get your podcasts.

Equifax Senior Advisor Tom O'Neill sits down with Ian Wright, Chief Strategy Officer at IXI, to unpack the shifting landscape of consumer wealth in a post-COVID economy. Drawing on exclusive IXI data, they explore how total U.S. household assets have grown to over $66 trillion—while the median household has actually lost ground. The conversation dives into the shrinking mass affluent segment, the rising influence of retirees, regional trends in affluence, and how financial institutions can better target high-potential markets. Economist Justin Begley of Moody's Analytics delivers our macroeconomic update.In this episode:·      Post-COVID wealth trends and overall asset growth·      The shrinking mass affluent segment and rise of the “barbell effect”·      Disparities in wealth distribution across income tiers·      Differences in financial outcomes by age group (Gen Z, Gen X, retirees)·      Geographic variations in wealth concentration·      Stock market and investments as primary drivers of wealth growth·      Declining deposit levels and implications for banks·      K-shaped economic and credit recovery·      Strategic marketing approaches for targeting affluent households·      Outlook for deposits and investments through 2025–2026

This episode discusses a retrospective single-center study examined the effects of socioeconomic status on preemptive kidney transplantation in children.

AEM Podcast host Ken Milne, MD, and guest skeptic Suchismita Datta, MD, interview lead author Rachel E. Solnick, MD, MSc. Learn more in the accompanying Hot Off the Press article available in The Skeptics' Guide to Emergency Medicine.

Join James Burroughs as he sits down with Dr. Joseph L. Wright, Chief Health Equity Officer and Senior Vice President at the American Academy of Pediatrics. In this episode, they delve into the significance of providing equitable care, the journey towards achieving equity in clinical guidance, and the empowerment of learners in the healthcare field.

The underlying causes of health disparities are many, and sometimes healthcare providers can exacerbate disparities with how they operate. Health equity researchers have conducted "secret shopper" studies, revealing how healthcare providers limit appointments — and even treatment recommendations — to people with certain types of insurance. “Patients with Medicaid were significantly less likely to be offered appointments compared to those with Medicare or private insurance, and in many cases, clinics told us they weren't accepting any new Medicaid patients or that they didn't take Medicaid at all,” says Dr. Daniel Wiznia, Associate Professor of Orthopaedics & Rehabilitation at Yale and a former member of Movement Is Life's Steering Committee. “But when we would call back with private insurance, suddenly they have plenty of appointments available for the private insurance patients,” he says. Wiznia and his colleagues also found that even when Medicaid patients were offered appointments, wait times were often much longer — delays which can have serious consequences.  “So if a Medicaid patient has to wait six weeks or eight weeks for an appointment, while a private patient just waits maybe a week, that can really impact outcomes, especially for patients with chronic conditions or urgent needs,” he says. Wiznia joined Movement Is Life's Dr. Mary O'Connor to discuss these findings in detail. He offers advice to patients who may find themselves in a situation where they're denied care due to their insurance status and explains how raising reimbursement rates for Medicaid could help address the problem. Never miss an episode – be sure to subscribe to The Health Disparities podcast from Movement Is Life on Apple Podcasts, YouTube, or wherever you get your podcasts.

The incidence of early onset colorectal cancer (EOCRC) has been rising prompting the change in change in screening guidelines to 45 years of age for average risk patients. Join us for an in-depth discussion with guest speakers Dr. Andrea Cercek and Dr. Nancy You, where we provide a comprehensive look at the growing challenge of EOCRC. Hosts: - Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center - Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian - Dr. Phil Bauer, Graduating Colorectal Surgical Oncology Fellow at Memorial Sloan Kettering Cancer Center  - Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer Center - Dr. Andrea Cercek - Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center - Dr. Y. Nancy You, MD MHSc - Professor, Department of Colon and Rectal Surgery at MD Anderson Cancer Center Learning objectives:  - Describe trends in incidence of colorectal cancer, with emphasis on the rise of EOCRC. - Identify age groups and demographics most affected by EOCRC. - Summarize USPSTF recommendations for colorectal cancer screening. - Distinguish between screening methods (e.g., colonoscopy, FIT-DNA) and their sensitivity. - Understand treatment approaches for colon and rectal cancer (CRC) - Understand the role of mismatch repair (MMR) status in guiding treatment. - Outline the importance of genetic counseling and testing in young patients. - Discuss racial, ethnic, and socioeconomic disparities in CRC incidence and outcomes. - Describe the impact of cancer treatment on fertility and sexual health. -  Review fertility preservation options. - Identify the value of integrated care teams for young CRC patients. References: 1.         Siegel, R. L. et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. JNCI J. Natl. Cancer Inst. 109, djw322 (2017). https://pubmed.ncbi.nlm.nih.gov/28376186/ 2.         Abboud, Y. et al. Rising Incidence and Mortality of Early-Onset Colorectal Cancer in Young Cohorts Associated with Delayed Diagnosis. Cancers 17, 1500 (2025). https://pubmed.ncbi.nlm.nih.gov/40361427/ 3.         Phang, R. et al. Is the Incidence of Early-Onset Adenocarcinomas in Aotearoa New Zealand Increasing? Asia Pac. J. Clin. Oncol.https://pubmed.ncbi.nlm.nih.gov/40384533/ 4.         Vitaloni, M. et al. Clinical challenges and patient experiences in early-onset colorectal cancer: insights from seven European countries. BMC Gastroenterol. 25, 378 (2025). https://pubmed.ncbi.nlm.nih.gov/40375142/ 5.         Siegel, R. L. et al. Global patterns and trends in colorectal cancer incidence in young adults. (2019) doi:10.1136/gutjnl-2019-319511. https://pubmed.ncbi.nlm.nih.gov/31488504/ 6.         Cercek, A. et al. A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. J. Natl. Cancer Inst. 113, 1683–1692 (2021). https://pubmed.ncbi.nlm.nih.gov/34405229/ 7.         Zheng, X. et al. Comprehensive Assessment of Diet Quality and Risk of Precursors of Early-Onset Colorectal Cancer. JNCI J. Natl. Cancer Inst. 113, 543–552 (2021). https://pubmed.ncbi.nlm.nih.gov/33136160/ 8.         Standl, E. & Schnell, O. Increased Risk of Cancer—An Integral Component of the Cardio–Renal–Metabolic Disease Cluster and Its Management. Cells 14, 564 (2025). https://pubmed.ncbi.nlm.nih.gov/40277890/ 9.         Muller, C., Ihionkhan, E., Stoffel, E. M. & Kupfer, S. S. Disparities in Early-Onset Colorectal Cancer. Cells 10, 1018 (2021). https://pubmed.ncbi.nlm.nih.gov/33925893/ 10.       US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 325, 1965–1977 (2021). https://pubmed.ncbi.nlm.nih.gov/34003218/ 11.       Fwelo, P. et al. Differential Colorectal Cancer Mortality Across Racial and Ethnic Groups: Impact of Socioeconomic Status, Clinicopathology, and Treatment-Related Factors. Cancer Med. 14, e70612 (2025). https://pubmed.ncbi.nlm.nih.gov/40040375/ 12.       Lansdorp-Vogelaar, I. et al. Contribution of Screening and Survival Differences to Racial Disparities in Colorectal Cancer Rates. Cancer Epidemiol. Biomarkers Prev. 21, 728–736 (2012). https://pubmed.ncbi.nlm.nih.gov/22514249/ 13.       Ko, T. M. et al. Low neighborhood socioeconomic status is associated with poor outcomes in young adults with colorectal cancer. Surgery 176, 626–632 (2024). https://pubmed.ncbi.nlm.nih.gov/38972769/ 14.       Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A. & Jemal, A. Colorectal cancer statistics, 2023. CA. Cancer J. Clin. 73, 233–254 (2023). https://pubmed.ncbi.nlm.nih.gov/36856579/ 15.       Jain, S., Maque, J., Galoosian, A., Osuna-Garcia, A. & May, F. P. Optimal Strategies for Colorectal Cancer Screening. Curr. Treat. Options Oncol. 23, 474–493 (2022). https://pubmed.ncbi.nlm.nih.gov/35316477/ 16.       Zauber, A. G. The Impact of Screening on Colorectal Cancer Mortality and Incidence: Has It Really Made a Difference? Dig. Dis. Sci. 60, 681–691 (2015). https://pubmed.ncbi.nlm.nih.gov/25740556/ 17.       Edwards, B. K. et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116, 544–573 (2010). https://pubmed.ncbi.nlm.nih.gov/19998273/ 18.       Cercek, A. et al. Nonoperative Management of Mismatch Repair–Deficient Tumors. New England Journal of Medicine 392, 2297–2308 (2025). https://pubmed.ncbi.nlm.nih.gov/40293177/ 19.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Molecular Heterogeneity in Early-Onset Colorectal Cancer: Pathway-Specific Insights in High-Risk Populations. Cancers 17, 1325 (2025). https://pubmed.ncbi.nlm.nih.gov/40282501/ 20.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Ethnicity-Specific Molecular Alterations in MAPK and JAK/STAT Pathways in Early-Onset Colorectal Cancer. Cancers 17, 1093 (2025). https://pubmed.ncbi.nlm.nih.gov/40227607/ 21.       Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. JNCCN 19, 329–359 (2021). https://pubmed.ncbi.nlm.nih.gov/33724754/ 22.       Christenson, E. S. et al. Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancer. https://pubmed.ncbi.nlm.nih.gov/40388545/ 23.       Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. The Lancet 402, 41–53 (2023). https://pubmed.ncbi.nlm.nih.gov/37331369/ 24.       Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023). https://pubmed.ncbi.nlm.nih.gov/37142372/ 25.       Sauer, R. et al. Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. N. Engl. J. Med. 351, 1731–1740 (2004). https://pubmed.ncbi.nlm.nih.gov/15496622/ 26.       Cercek, A. et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol. 4, e180071 (2018). https://pubmed.ncbi.nlm.nih.gov/29566109/ 27.       Garcia-Aguilar, J. et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J. Clin. Oncol. 40, 2546–2556 (2022). https://pubmed.ncbi.nlm.nih.gov/35483010/ 28.       Schrag, D. et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N. Engl. J. Med. 389, 322–334 (2023). https://pubmed.ncbi.nlm.nih.gov/37272534/ 29.       Kunkler, I. H., Williams, L. J., Jack, W. J. L., Cameron, D. A. & Dixon, J. M. Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. N. Engl. J. Med. 388, 585–594 (2023). https://pubmed.ncbi.nlm.nih.gov/36791159/ 30.       Jacobsen, R. L., Macpherson, C. F., Pflugeisen, B. M. & Johnson, R. H. Care Experience, by Site of Care, for Adolescents and Young Adults With Cancer. JCO Oncol. Pract. (2021) doi:10.1200/OP.20.00840. https://pubmed.ncbi.nlm.nih.gov/33566700/ 31.       Ruddy, K. J. et al. Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer. J. Clin. Oncol. (2014) doi:10.1200/JCO.2013.52.8877. https://pubmed.ncbi.nlm.nih.gov/24567428/ 32.       Su, H. I. et al. Fertility Preservation in People With Cancer: ASCO Guideline Update. J. Clin. Oncol. 43, 1488–1515 (2025). https://pubmed.ncbi.nlm.nih.gov/40106739/ 33.       Smith, K. L., Gracia, C., Sokalska, A. & Moore, H. Advances in Fertility Preservation for Young Women With Cancer. Am. Soc. Clin. Oncol. Educ. Book 27–37 (2018) doi:10.1200/EDBK_208301. https://pubmed.ncbi.nlm.nih.gov/30231357/ 34.       Blumenfeld, Z. How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries. The Oncologist 12, 1044–1054 (2007). 35.       Bhagavath, B. The current and future state of surgery in reproductive endocrinology. Curr. Opin. Obstet. Gynecol. 34, 164 (2022). 36.       Ribeiro, R. et al. Uterine transposition: technique and a case report. Fertil. Steril. 108, 320-324.e1 (2017). 37.       Yazdani, A., Sweterlitsch, K. M., Kim, H., Flyckt, R. L. & Christianson, M. S. Surgical Innovations to Protect Fertility from Oncologic Pelvic Radiation Therapy: Ovarian Transposition and Uterine Fixation. J. Clin. Med. 13, 5577 (2024). 38.       Holowatyj, A. N., Eng, C. & Lewis, M. A. Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer. JCO Oncol. Pract. 18, 169–172 (2022). ***Behind the Knife Colorectal Surgery Oral Board Audio Review: https://app.behindtheknife.org/course-details/colorectal-surgery-oral-board-audio-review Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

July 17, 2025: Chris Harper, CIO and Senior Associate Vice Chancellor of AI at the University of Kansas Medical Center, discusses the nuances of AI governance. Chris discusses why he'd rather be "a pro than a hero" and how this philosophy shapes his collaborative leadership style in implementing AI solutions. They explore his organization's strategic technology bets over two decades, from meaningful use to data analytics to AI automation, and reveal how building trust with clinical partners has become the foundation for successful innovation. Through insights on governance across multiple organizational structures and his "move fast and be responsible" methodology, Chris offers practical wisdom for healthcare leaders preparing for what he sees as a paradigm shift in how technology will reshape the industry. Key Points: 03:55 Governance and Decision Making 10:33 Leadership and Team Collaboration 21:37 Disparities in Rural Areas 27:01 Challenges for Healthcare CIOs 30:01 Speed Round and Closing Remarks X: This Week Health LinkedIn: This Week Health Donate: Alex's Lemonade Stand: Foundation for Childhood Cancer

In this episode of One in Ten, Teresa Huizar speaks with Dr. Vanessa Bouché, research fellow at the LBJ School of Public Affairs, about child sex trafficking and the 25-year impact of the Trafficking Victims Protection Act (TVPA). The conversation delves into the origins and patterns of child sex trafficking, the federal and state legislative responses, and the importance of empirical data in shaping effective policies. Dr. Bouché shares insights from her studies, highlighting the intersection with other forms of child abuse and the need for increased prevention efforts. The episode also explores the role of technology and corporate accountability in combating trafficking, and the importance of addressing the root causes and behaviors leading to both victimization and perpetration.  Time  Topic 00:00 Introduction and Guest Introduction 00:24 The Trafficking Victims Protection Act (TVPA) 01:25 Dr. Bouché 's Journey into Human Trafficking Research 03:15 Challenges in Data Collection and Prosecution 04:12 Federal vs. State Prosecutions 06:39 Trends and Challenges in Human Trafficking Cases 14:48 The Role of Technology and Online Exploitation 18:28 Prevention and Legislative Gaps 24:06 Corporate Accountability and Public Responsibility 31:48 Intersectionality and Vulnerable Populations 37:28 Future Research and Concluding Thoughts Resources:Federal Human Trafficking Prosecution Data: Identifying Trends, Gaps, and Disparities to Advance Evidence-Based ReformsSupport the showDid you like this episode? Please leave us a review on Apple Podcasts.

Welcome to the sixth season of the Dementia Researcher X ISTAART PIA Relay Podcast. This series features interviews with ISTAART PIA committee members talking about their research, the research landscape of their fields, and the work of the ISTAART Professional Interest Areas (PIA) they represent. As we build up to the Alzheimer's Association International Conference in Toronto, join us for daily episodes that showcase the remarkable work being done in various research fields. -- In this episode, Professor Owen Carmichael talks with Dr Shana Stites, Assistant Professor at University of Pennsylvania and Chair of the ISTAART Diversity and Disparities PIA. In this discussion they explore the importance of inclusive participation in dementia research, the challenges of equitable access to research and care, and the shift toward more community-engaged approaches. The conversation highlights barriers like limited access to healthcare, the ethics of stipends, and the value of transparency, reciprocity, and representation in Alzheimer's disease and related research. They also talk about the wider work and aims of the PIA and what they have planned for the upcoming AAIC. -- The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) convenes the global Alzheimer's and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer's and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. -- There are currently 30 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: http://www.istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year's AAIC (In-person and online) visit: http://www.aaic.alz.org -- Find more information on our guests, and a full transcript of this podcast on our website at: http://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]

Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]

Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]

Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]

On WPFW FM 89.3 Pacifica Radio, Nathan Taylor of the Election Truth Alliance joins Make It Plain with Rev. Mark and Joy Reid to discuss his research on the 2024 election. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Disparities in Treatment and Referral After an Opioid Overdose Among Emergency Department Patients  JAMA Network Open This cohort study of 1,683 patients assessed if there are racial and ethnic disparities in treatment referral rates among patients in the emergency department (ED) with opioid overdose.  It found a statistically significant difference in the proportion of Black patients who received an outpatient treatment referral (5.7%) compared with White patients (9.6%). These findings suggest that Black patients presenting to the ED with opioid overdose may be less likely to receive outpatient treatment referrals, underscoring the need for targeted intervention and enhanced referral processes.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

The podcast crew takes on the topic of prehospital analgesia. What pain medication do we choose when facing a complex patient with all analgesics available? Are there better options for hypotensive patients? What about pregnancy and the elderly? On this episode, we'll walk through our MCHD pain medication options, take a moment for a BLS reminder, and discuss some specific situations where certain medications are the best fit. REFERENCES 1. McArthur, R., Cash, R. E., Rafique, Z., Dickson, R., Crocker, K., Crowe, R. P., Wells, M., Chu, K., Nguyen, J., & Patrick, C. (2024). Intravenous Acetaminophen Versus Ketorolac for Prehospital Analgesia: A Retrospective Data Review. The Journal of emergency medicine, 67(3), e259–e267. 2. McArthur, R., Cash, R. E., Anderson, J., De La Rosa, X., Peckne, P., Hogue, D., Badawood, L., Secrist, E., Andrabi, S., & Patrick, C. (2025). Fentanyl versus nebulized ketamine for prehospital analgesia: A retrospective data review. The American journal of emergency medicine, 89, 124–128. 3. Powell, J. R., Browne, L. R., Guild, K., Shah, M. I., Crowe, R. P., Lindbeck, G., Braithwaite, S., Lang, E. S., Panchal, A. R., & Technical Expert Panel (2023). Evidence-Based Guidelines for Prehospital Pain Management: Literature and Methods. Prehospital emergency care, 27(2), 154–161. 4. Aceves, A., Crowe, R. P., Zaidi, H. Q., Gill, J., Johnson, R., Vithalani, V., Fairbrother, H., & Huebinger, R. (2023). Disparities in Prehospital Non-Traumatic Pain Management. Prehospital emergency care, 27(6), 794–799.

This week's podcast is dedicated to Circulation's fifth annual Disparities issue. First, please join Associate Editor Karol Watson and Guest Editor Nilay Shah as they discuss the article "Centering Diné (Navajo) Voices: Barriers, Facilitators, and Perceptions of Cardiac Care Among Patients With Heart Failure in Rural Navajo Nation" with corresponding author Lauren Eberly. Then, Associate Editor Mercedes Carnethon and Guest Editor Nilay Shah discuss the Frame of Reference article "Health Equity: Are We There Yet?" with author Clyde Yancy. Don't miss this important episode! For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20250710.251438

What does it take to create healthy neighborhoods that include broad, deep, and permanent pathways to prosperity for low-income families?  That question is the focus of today's episode with Carol Redmond Naughton, CEO of Purpose Built Communities based in Atlanta. “I really have become an  advocate for community development as a way to move the needle on  health outcomes. And I'm not talking about simply putting a kidney dialysis center in the bottom floor of a senior high rise,” Naughton says. “I don't mean to say that that's not a good thing to do, but we've got to move upstream. We've got to be way upstream and be thinking about: How are we building communities and supporting children, so those children 60 years from now will not need kidney dialysis?” In a conversation that was first published in 2022, Naughton speaks with Movement Is Life's Dr. Tamara Huff about the difference between access to health care and health outcomes and the importance of addressing the social determinants of health.   She also calls on all of us to reflect on the systems that have kept people trapped in poverty — especially Black and Brown communities — and consider what it takes to create communities that support a “cradle to college pipeline.”  Never miss an episode – be sure to subscribe to The Health Disparities podcast from Movement Is Life on Apple Podcasts, YouTube, or wherever you get your podcasts.

Disparities in access to surgical resection in patients with pancreatic cancer - a systematic review

In this episode RCP Medicine Podcast, we are joined by Dr John Dean, Clinical Vice President at the Royal College of Physicians and a physician in East Lancashire, and Dr John Ford, an academic public health doctor and Senior Clinical Lecturer at Queen Mary University. Together. They explore the multifaceted nature of health inequalities and discuss actionable steps physicians can take to address these disparities. Both share their personal experiences and professional insights into health inequalities and how it shaped their understanding of social and economic disadvantages. They discuss the structural factors within society that lead to health inequalities and emphasise the importance of creating a fairer, more inclusive society. The conversation focusses on the role of clinicians in addressing health care inequalities and the need for continuous improvement in healthcare design and delivery.ResourcesBridging the gap: a guide to making health inequalities a strategic priority for NHS leadersA snapshot of UK doctors: experiences of health inequalitiesSupporting clinicians to address health inequalities in practiceRCP view on health inequalities: a call to action for a cross-government strategyRCP LinksEducation and learning | RCP Events | RCP Membership | RCP Improving care | RCP Policy and campaigns | RCP RCP Social MediaInstagramLinkedInFacebookXBlueskyCreditsMusic by bensound.comFundingThis episode was funded by Vertex Pharmaceuticals (Europe) Limited. Vertex had no involvement in the creation and elaboration of this episode and all views and opinions expressed by the presenter and guests are solely their own.

“The five-year relative survival rate for localized, or cancer that is confined to the colon or the rectum, is 91% for colon cancer and 90% for rectal cancer. Distant, metastasized to other organs—the five-year survival rate is 13% for colon and 18% for rectal cancer. So that really shows you the huge difference in screening and where screening can come in and make better outcomes,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer screening. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 4, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Leaners will report an increase in knowledge related to colorectal screening, early detection, and disparities. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episode: Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: AI-Assisted Colonoscopy Can Detect Small Colon Polyps As Colorectal Cancer Incidence Increases in Younger Patients, USPSTF Issues New Screening Guidelines. Here's How Nurses Can Encourage Uptake Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Text Messaging Reduces Disparities in Colorectal Cancer Screening USPSTF Recommends Colorectal Cancer Screening Should Begin at 45 Clinical Journal of Oncology Nursing articles: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Colorectal Cancer Screening: A Quality Improvement Initiative Using a Bilingual Patient Navigator, Mobile Technology, and Fecal Immunochemical Testing to Engage Hispanic Adults Oncology Nursing Forum article: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data ONS Course: Prevention, Detection, and the Science of Cancer—Oncology RN ONS Biomarker Database ONS Colorectal Cancer Learning Library American Cancer Society colorectal cancer resources Colorectal Cancer Alliance To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Interestingly, recent studies suggest that starting screening even earlier than 45, such as age 40, could significantly reduce mortality and incidence rates, especially as colorectal cancer is rising among younger adults.” TS 2:42 “[Artificial intelligence]-enhanced screening tools are also being developed to improve sensitivity, reduce turnaround time, and enable real-time monitoring of disease progression. These innovations aim to make screening more accessible and accurate, especially in our underserved populations. So there's a huge impact on early detection.” TS 4:07 “Those with multiple chronic conditions or limited mobility may be less likely to complete screening, and those results may be harder to interpret. I mentioned a little bit earlier about our underserved or minority populations. Those barriers such as limited health literacy, lack of insurance, and cultural stigma can reduce screening uptake and ultimately follow-through.” TS 12:25 “Patient navigation programs—this is where we have trained navigators to help patients schedule appointments, understand procedures, and ultimately overcome some of these logistical hurdles. These have actually been shown to significantly boost screening rates. Also, those mailed stool-based-test kits—sending those kits directly to a patient home, especially with a personalized letter from a provider to add that extra little touch, has proven effective in increasing participation.” TS 21:29 “Our screening can detect cancer before symptoms appear and even identify precancerous polyps, which can be removed to prevent cancer altogether. Studies actually show that regular screening can reduce colorectal cancer mortality by up to 35% and the incidence of advanced-stage disease by nearly 30%. Just another reason why screening really does matter.” TS 25:53 “Evaluating our implicit bias, especially in something as critical as colorectal cancer, requires both introspection and instructional supports. One way of doing this is by auditing your practice patterns, really looking at reviewing your own screening recommendations and follow-up rates across different patient demographics. So are there certain groups that are less likely to be offered a colonoscopy? I think some of us may have an implicit bias—you see a patient; you're like, ‘There's no way they're going to agree to that, so I'm just not going to offer it.' Where we don't offer it, they don't have that opportunity to decline that. That can lead to further delay. And those patterns can reveal a bias in action.” TS 28:18

The McCullough Report with Dr. Peter McCullough – USA Facts reinterprets CDC data to reveal that 81% of Americans received at least one COVID-19 shot, yet only 70% achieved full vaccination. Disparities persist across demographics, with low coverage in infants. Critics lambaste CDC's transparency and the FDA's new framework. With booster uptake below 15%, concerns arise about pharma influence and public health policy...

The McCullough Report with Dr. Peter McCullough – USA Facts reinterprets CDC data to reveal that 81% of Americans received at least one COVID-19 shot, yet only 70% achieved full vaccination. Disparities persist across demographics, with low coverage in infants. Critics lambaste CDC's transparency and the FDA's new framework. With booster uptake below 15%, concerns arise about pharma influence and public health policy...

In this podcast, expert clinicians discuss racial, ethnic, and socioeconomic disparities that have been identified in accessing IBD care, disease management, and treatment outcomes.

Reference: Solnick et al. Sex Disparities in Chlamydia and Gonorrhea Treatment in US Adult Emergency Departments: A Systematic Review and Meta-analysis. AEM June 2025 Date: June 24, 2025 Guest Skeptic: Dr. Suchismita Datta. She is an Assistant Professor and Director of Research in the Department of Emergency Medicine at the NYU Grossman Long Island Hospital […] The post SGEM#478: If I Were a Man: Sex-Based Disparities in the Treatment of STIs first appeared on The Skeptics Guide to Emergency Medicine.

Today's episode focuses on a recent article in JAMA Internal Medicine regarding maternal mental health in the United States. I'll explain and summarize the study and results, and discuss the most appropriate next steps. Since I'm presenting the information in summary form, please read the article for yourself by clicking the link in the Resources section for this episode.  Show Highlights: The findings of this study are sobering and validating. Scope and value of research findings like this to “fill the gap” in maternal mental health The details of the study subjects: 198,000+ US mothers from 2016-2023 who self-reported their physical and mental health The key findings: The percentage of mothers reporting a rating of “excellent” mental health dropped dramatically during the time frame, the percentage reporting “fair” or “poor” mental health increased, and the trend of declining maternal mental health crosses through all socio-economic groups. The key factors contributing to maternal mental health conditions  Results of the study show that we need more investment into the underlying causes of mental health decline, especially for lower socio-economic status moms. Moms are suffering under the weight of silence, stigma, shame, and societal expectations. Studies like this one are vital to break down barriers to care and support. Learning to identify your needs, choose rest when needed, and prioritize self-compassion What we can do to help: offer screenings at multiple points, effect policy change, and find positive ways to support the entire family system. Resources: Read the JAMA article, “Trends and Disparities in Maternal Self-Reported Mental and Physical Health.” Click here. Call the National Maternal Mental Health Hotline at 1-833-TLC-MAMA or visit cdph.ca.gov Please find resources in English and Spanish at Postpartum Support International, or by phone/text at 1-800-944-4773. There are many free resources available, including online support groups, peer mentors, a specialist provider directory, and perinatal mental health training for therapists, physicians, nurses, doulas, and anyone who wants to become more supportive in offering services.  You can also follow PSI on social media: Instagram, Facebook, and most other platforms Visit www.postpartum.net/professionals/certificate-trainings/ for information on the grief course.   Visit my website, www.wellmindperinatal.com, for more information, resources, and courses you can take today! If you are a California resident looking for a therapist in perinatal mental health, email me about openings for private pay clients! Learn more about your ad choices. Visit podcastchoices.com/adchoices

The case for diversity in healthcare professions is strong. Research shows that a diverse healthcare workforce improves health outcomes, particularly for patients of color, and also increases people's access to care and their perception of the care they receive.  Physicians of color are more likely to build careers in underserved communities, which can contribute even more toward the goal of reducing healthcare disparities. So, what does it take to cultivate a strong and diverse health care workforce? On this week's episode, we gain insights from two knowledgeable guests, who spoke with Dr. Hadiya Green at  Movement Is Life's annual summit: Dr. Cheryl Brewster, Senior Executive Dean for Access, Opportunity, and Collaboration and a Professor in the Department of Bioethics, Humanism, and Policy Roseman University College of Medicine Dr. Jarrod Lockhart, formerly an instructor at Morehouse School of Medicine, now Assistant Vice Provost, Education Outreach & Collaboration at Oregon Health & Science University Never miss an episode – be sure to subscribe to The Health Disparities podcast from Movement Is Life on Apple Podcasts, YouTube, or wherever you get your podcasts.

Story at-a-glance Autism rates in the U.S. have surged by 17% in just two years, with 1 in 31 children now affected — a public health crisis experts say must no longer be ignored Most diagnosed children have intellectual disabilities, debunking claims that rising rates are due to better detection of mild cases The U.S. Centers for Disease Control and Prevention (CDC) report omitted environmental factors entirely, despite mounting research linking toxins like glyphosate, heavy metals, and EMFs to neurological harm and autism-related outcomes Health Secretary Robert F. Kennedy Jr. is launching an unprecedented investigation into environmental triggers, urging researchers to “follow the science” and deliver initial findings by September to guide future action Disparities in autism rates across racial groups raise urgent questions, as Asian, Black, and Hispanic children face significantly higher diagnoses — a signal that systemic and environmental factors demand deeper scrutiny

In this episode David Kaufman, MD, FAAP, discusses postnatal cord blood sampling and testing. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Prabi Rajbhandari, MD, FAAP, about disparities in preventive care for children from English and non-English-speaking households. For resources go to aap.org/podcast.

From Small Town Georgia to Hollywood Fame: Actress Ellia English Tells It Like It Is – Part 2!In this powerful and unfiltered episode of the Lin. Woods Gospel Entertainment Podcast, beloved Hollywood TV actress Ellia English (The Jamie Foxx Show, Martin, HBO's Curb Your Enthusiasm, My Sisters and Me)  shares the backstory of her inspiring journey.She opens up about navigating the ups and downs of showbiz, and what it really takes to succeed as a Black woman in Hollywood. Plus, hear her bold take on Taraji P. Henson's revelations about pay inequality for Black actors—and why this conversation matters.Listen FREE, Subscribe FREE, Download FREE – and be inspired by the wisdom, warmth, and real talk of Ellia English.#LinWoodsGospelEntertainmentPodcast #OfficiallyElliaEnglish #BlackHollywood #Podcast #FaithAndFame

Stroke Rates Among Hispanic IndividualsThe Hispanic population has experienced an increase in stroke incidence since 2013.A CDC report showed that just 58% of Hispanic adults could identify symptoms of a stroke, compared to their Black (64%) and white (71%) peers.Stroke ranks as the fourth leading cause of death for Hispanic men and the third for Hispanic women in the U.S.Disparities in CareIn studies that detected racial disparities in emergency services, EMS usage was lower by as much as 40% in Hispanic patients.A greater proportion of white patients (37.4%) were estimated to arrive within 3 hours from onset of stroke symptoms than Hispanic (28.9%) patients. Hispanic patients had the highest rate of discharge to home without home health care services (49.1%) and the lowest rate of facility-based rehabilitation service utilization after stroke.In border states, Hispanic individuals who experienced ischemic stroke were 30% more likely to suffer in-hospital mortality vs. their non-Hispanic counterparts.Why Is Stroke an Emergency?Nearly 2 million brain cells die every minute that an ischemic stroke goes untreated.Not all strokes are the same, which means each requires unique treatment at specialized stroke centers from highly trained stroke care teams.Lowering Chance of Lifelong Disability or DeathKnow the signs of stroke and call 911 immediately. Modeled after BE FAST, the Spanish acronym RÁPIDO was created to raise awareness of stroke symptoms in the Hispanic community.Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-unplugged-totally-uncut--994165/support.

Are your thoughts your own, or are they being manipulated through A.I. and social media? Many of us have been victims of synthetic telepathy. Tune in to hear our recent thoughts on this topic.

Joss, a member of the LGBTQ community, was also of Comanche and White Mountain Apache descent. His death highlights a crisis of underreported mental health disparities.

A study released this month examined the state of mothers' mental health in the U.S. from 2016 to 2023. Using data from 200,000 mothers, the study reveals a "significant decline" in emotional and physical well-being for mothers in all age groups and demographics. Margaret and Amy break down the data, the implications, and the causes—which certainly include the pandemic, although there are many other social, economic, and cultural forces contributing to the stress of modern motherhood. Amy and Margaret discuss: What a major national study reveals about maternal mental health trends Why the decline in mental health extends far beyond the postpartum period The role of pandemic-related stress, financial pressures, and lack of support How parents can prioritize their own well-being—even in small, actionable ways Why maternal mental health impacts the whole family system Mothers' mental health is showing up as a true crisis, and not just in the postpartum months, but throughout the parenting journey. The clear connection between children's mental health and that of their caregivers makes maternal well-being an imperative public health priority. Here are links to some of the resources mentioned in the episode: Catherine Pearson for the New York Times: Study Finds a Steep Drop in Mothers' Mental Health Daw JR, MacCallum-Bridges CL, Admon LK: Trends and Disparities in Maternal Self-Reported Mental and Physical Health. JAMA Intern Med.  Sara Moniuszko for CBS News: Moms in the U.S. report large decline in mental health in recent years, study finds Elizabeth Tenety for Motherly: Just 1 in 4 moms say they're doing well mentally—new study reveals a growing crisis Reddit/Health: Moms in the U.S. report large decline in mental health in recent years, study finds Pooja Lakshmin MD on Substack: Mental health is personal — and political Our Fresh Take with Pooja Lakshmin on Burnout and Mom Guilt We love the sponsors that make this show possible! You can always find all the special deals and codes for all our current sponsors on our website: ⁠⁠https://www.whatfreshhellpodcast.com/p/promo-codes/⁠⁠ mom friends, funny moms, parenting advice, parenting experts, parenting tips, mothers, families, parenting skills, parenting strategies, parenting styles, busy moms, self-help for moms, manage kid's behavior, teenager, tween, child development, family activities, family fun, parent child relationship, decluttering, kid-friendly, invisible workload, default parent, household equity, household equality, gender household equality, gender household equity, anxiety, maternal mental health, postpartum health, PPD, PPA, PPOCD Learn more about your ad choices. Visit podcastchoices.com/adchoices

Poverty is a key driver of health disparities. But numerous policies have been shown to help alleviate poverty and improve health equity, according to Dr. Rita Hamad, associate professor of social and behavioral sciences at the Harvard T.H. Chan School of Public Health. Hamad says policymakers need to look upstream and identify the root causes of health issues. “And really recognizing that poverty is one of the major root causes of those issues, and that if we don't address that… those health issues are just going to keep arising and not getting any better,” she says.  On this episode of the Health Disparities podcast, Hamad speaks with Movement Is Life's Dr. Charla Johnson about evidence-based policies for alleviating poverty — like the child tax credit, earned income tax credit — and explains how healthcare systems can get more involved in bolstering the social safety net. Never miss an episode – be sure to subscribe to The Health Disparities podcast from Movement Is Life on Apple Podcasts, YouTube, or wherever you get your podcasts.

Send us a textMegan and Michelle learn about the Pygmalion Effect, nerd persons, squeaky wheels, living statues, elevated expectations, accidental fans, and finding the right path. Sources:Why do we perform better when someone has high expectations of us?Study Furthers Understanding of Disparities in School DisciplineGolem Effect (Wikipedia)****************Want to support Prosecco Theory?Become a Patreon subscriber and earn swag!Check out our merch, available on teepublic.com!Follow/Subscribe wherever you listen!Rate, review, and tell your friends!Follow us on Instagram!****************Ever thought about starting your own podcast? From day one, Buzzsprout gave us all the tools we needed get Prosecco Theory off the ground. What are you waiting for? Follow this link to get started. Cheers!!Support the show

On Friends Like Us, host Marina Franklin dives deep into critical discussions on black maternal health with the incredible Dr. Wylin D. Wilson and comedian Ashima Franklin. Empower yourself with knowledge, laughter, and inspiration!  Wylin D. Wilson is Associate Professor of Theological Ethics at Duke Divinity School where she teaches Womanist Bioethics within the Theology Medicine and Culture program. She is author of Economic Ethics and the Black Church and Womanist Bioethics: Social Justice, Spirituality, and Black Women's Health. Ashima Franklin is a comedian, writer and actor, born and raised in Mobile, AL. Recently, she was selected as one of the inaugural 2024 NETFLIX IS A JOKE… Introducing (New Faces) comedians. In addition, she was also selected “Best of Fest” at Moontower Comedy Festival in Austin. She also performed in comedy festivals like Flyover Comedy Fest, Laughing Skull and New York Comedy Festival. Previously, she toured the country for 5 years with Katt Williams on the Priceless, The Katt Pack and Katapocolypse tours. . As an actor, she also appeared in the movie THE AFTERPARTY on Netflix. Ashima recently appeared on the ALLBLK Network on the Kendall Kyndall show with Drew Sadora, as well as Season 2 of OWN's READY TO LOVE. In addition, she appeared on Kountry Wayne's COMEDY SHIT (Youtube), in which she is currently a recurring cast member. Ashima also headlined the Vivica Fox Funny by Nature Tour. Ashima was selected to be a part of the 2022 & 2023 New York Comedy Festival. Always hosted by Marina Franklin - One Hour Comedy Special: Single Black Female ( Amazon Prime, CW Network), TBS's The Last O.G, Last Week Tonight with John Oliver, Hysterical on FX, The Movie Trainwreck, Louie Season V, The Jim Gaffigan Show, Conan O'Brien, Stephen Colbert, HBO's Crashing, and The Breaks with Michelle Wolf. Writer for HBO's 'Divorce' and the new Tracy Morgan show on Paramount Plus: 'Crutch'.     

A diverse healthcare workforce is critical to improving outcomes for our diverse nation. In order to achieve this, there needs to be both a pipeline and a pathway, says Dr. Valerie Montgomery Rice, President and CEO of Morehouse School of Medicine. “We need students to believe what's possible in first grade and then chart a path,” she says. Montgomery Rice says her own love and science and people led her to chart her career pathway that led her into academic medicine. “What if everybody was given that opportunity. What if everybody was told you can be whatever you want to be?” “Every one of my roles has been about how to develop people to bring their best self to work,” she says. Although health equity work can be polarized and be perceived as political, Montgomery Rice says Morehouse School of Medicine is committed to leading the creation and advancement of health equity — both through new solutions and through complementing existing ones.  The heart of her message on health equity: It's about “giving people what they need, when they need it, to achieve optimal level of health.” Montgomery Rice spoke with Movement Is Life's Dr. Carla Harwell for this episode, which was recorded at Movement Is Life's annual health equity summit. Never miss an episode – be sure to subscribe to The Health Disparities podcast from Movement Is Life on Apple Podcasts, YouTube, or wherever you get your podcasts.

*Content warning: birth trauma, medical trauma, medical neglect, racism, death of an infant, infant loss, death, maternal loss, mature and stressful themes.*Free + Confidential Resources + Safety Tips: somethingwaswrong.com/resources Center for Black Maternal Health & Reproductive Justice:https://blackmaternalhealth.tufts.edu/Center for Black Maternal Health & Reproductive Justice Instagram:https://www.instagram.com/cbmhrj_tufts/Center for Black Maternal Health & Reproductive Justice Facebook:https://www.facebook.com/CBMHRJTufts/Center for Black Maternal Health & Reproductive Justice LinkedIn:https://www.linkedin.com/company/cbmhrjtufts/Sources: Addressing Transportation Barriers to Improve Healthcare Access in Arizonahttps://repository.arizona.edu/handle/10150/674794 Advancing Health Equity and Value-Based Care: A Mobile Approachhttps://info.primarycare.hms.harvard.edu/perspectives/articles/mobile-clinics-in-the-us-health-system#:~:text=Mobileclinicsareaproven,thecriticalweeksafterbirth American College of Nurse Midwiveshttps://midwife.org/ American College of Obstetricians and Gynecologists (ACOG)https://www.acog.org/ Birth Centers in Massachusettshttps://baystatebirth.org/birth-centers A Brief History of Midwifery in Americahttps://www.ohsu.edu/womens-health/brief-history-midwifery-america Clinical outcomes improve when patient's and surgeon's ethnicity match, study showshttps://www.uclahealth.org/news/article/clinical-outcomes-patients-surgeons-concordanceThe Controversial Birth of American Gynecologyhttps://researchblog.duke.edu/2023/10/27/the-controversial-birth-of-american-gynecology/ 'Father Of Gynecology,' Who Experimented On Slaves, No Longer On Pedestal In NYChttps://www.npr.org/sections/thetwo-way/2018/04/17/603163394/-father-of-gynecology-who-experimented-on-slaves-no-longer-on-pedestal-in-nyc Governor Healey Signs Maternal Health Bill, Expanding Access to Midwifery, Birth Centers and Doulas in Massachusettshttps://www.mass.gov/news/governor-healey-signs-maternal-health-bill-expanding-access-to-midwifery-birth-centers-and-doulas-in-massachusetts#:~:text=GovernorHealeySignsMaternalHealthBillCExpanding,ExecutiveOfficeofHealthandHumanServices Governor Murphy Signs Bill Establishing Maternal and Infant Health Innovation Centerhttps://www.nj.gov/governor/news/news/562023/approved/20230717a.shtml Helping Mothers and Children Thrive: Rethinking CMS's Transforming Maternal Health (TMaH) Modelhttps://www.milbank.org/quarterly/opinions/helping-mothers-and-children-thrive-rethinking-cmss-transforming-maternal-health-tmah-model/#:~:text=TheTransformingMaternalHealth(TMaH)Model&text=TheTMaHModelfocuseson,midwiferyservicesanddoulacare The Historical Significance of Doulas and Midwiveshttps://nmaahc.si.edu/explore/stories/historical-significance-doulas-and-midwivesInfant Health and Mortality and Black/African Americanhttps://minorityhealth.hhs.gov/infant-health-and-mortality-and-blackafrican-americans#:~:text=In2022%2Ctheinfantmortality,Figure2 Legislature Passes Comprehensive Maternal Health Billhttps://malegislature.gov/PressRoom/Detail?pressReleaseId=136Life Story: Anarcha, Betsy, and Lucyhttps://wams.nyhistory.org/a-nation-divided/antebellum/anarcha-betsy-lucy/Management of Postpartum Hemorrhage in Low- and Middle-Income Countries: Emergency Need for Updated Approach Due to Specific Circumstances, Resources, and Availabilitieshttps://pmc.ncbi.nlm.nih.gov/articles/PMC11643001/#:~:text=EtiologyandRiskFactorsof,insufficienttreatment%E2%80%9D%5B50%5D March of Dimeshttps://www.marchofdimes.org/peristats/about-us Maternity Care Deserthttps://www.marchofdimes.org/peristats/data?top=23 Maternal deaths and mortality rates by state, 2018-2022https://www.cdc.gov/nchs/maternal-mortality/mmr-2018-2022-state-data.pdf Maternal Mortality in the United States After Abortion Banshttps://thegepi.org/maternal-mortality-abortion-bans/#:~:text=In2023%2CTexas'smaternalmortality,suffermaternaldeathin2023 Maternal Mortality in the U.S Declined, though Disparities in the Black Population Persisthttps://policycentermmh.org/maternal-mortality-in-the-u-s-a-declining-trend-with-persistent-racial-disparities-in-the-black-population/Maternal Mortality Is on the Rise: 8 Things To Knowhttps://www.yalemedicine.org/news/maternal-mortality-on-the-rise Maternal Mortality: How the U.S. Compares to Other Rich Countrieshttps://www.usnews.com/news/best-countries/articles/2024-06-04/how-the-u-s-compares-to-other-rich-countries-in-maternal-mortalityMaternal Mortality Rates in the United States, 2021https://www.cdc.gov/nchs/data/hestat/maternal-mortality/2021/maternal-mortality-rates-2021.htm#:~:text=In2021%2C1%2C205womendied,20.1in2019(Table) Medical Exploitation of Black Womenhttps://eji.org/news/history-racial-injustice-medical-exploitation-of-black-women/National Midwifery Institutehttps://www.nationalmidwiferyinstitute.com/midwifery National Counsel of State Boards of Nursinghttps://www.ncsbn.org/North American Registry of Midwives (NARM)https://narm.org/ Outcome of subsequent pregnancies in women with complete uterine rupture: A population-based case–control studyhttps://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/aogs.14338#:~:text=outcomesarerare.-,1INTRODUCTION,experienceacompleteuterinerupture.&text=Completeuterineruptureisdefined,completeruptureofthemyometrium Pregnancy-Related Deaths: Data From Maternal Mortality Review Committees in 36 U.S. States, 2017–2019https://www.cdc.gov/maternal-mortality/php/data-research/mmrc-2017-2019.html Preterm Birthhttps://www.cdc.gov/maternal-infant-health/preterm-birth/index.html#:~:text=Pretermbirthrates&text=In2022%2Cpretermbirthamong,orHispanicwomen(10.1%25) Racial Disparities in Maternal and Infant Health: Current Status and Efforts to Address Themhttps://www.kff.org/racial-equity-and-health-policy/issue-brief/racial-disparities-in-maternal-and-infant-health-current-status-and-efforts-to-address-them/The Racist History of Abortion and Midwifery Banshttps://www.aclu.org/news/racial-justice/the-racist-history-of-abortion-and-midwifery-bans Reducing Disparities in Severe Maternal Morbidity and Mortalityhttps://pmc.ncbi.nlm.nih.gov/articles/PMC5915910/#:~:text=Severemorbidityposesanenormous,ofseverematernalmorbidityevents State investigating Dallas birth center and midwives, following multiple complaints from patientshttps://www.wfaa.com/article/news/local/investigates/state-investigating-dallas-birth-center-midwives-following-multiple-complaints-from-patients/287-ea77eb18-c637-44d4-aaa2-fe8fd7a2fcef The State of Telehealth Before and After the COVID-19 Pandemichttps://pmc.ncbi.nlm.nih.gov/articles/PMC9035352/ Texas Department of Licensing and Regulation (TDLR)https://www.tdlr.texas.gov/ U.S. maternal death rate increasing at an alarming ratehttps://news.northwestern.edu/stories/2024/03/u-s-maternal-death-rate-increasing-at-an-alarming-rate/Which states have the highest maternal mortality rates?https://usafacts.org/articles/which-states-have-the-highest-maternal-mortality-rates/ Why Equitable Access to Vaginal Birth Requires Abolition of Race-Based Medicinehttps://journalofethics.ama-assn.org/article/why-equitable-access-vaginal-birth-requires-abolition-race-based-medicine/2022-03 Zucker School of Medicine, Amos Grunebaum, MDhttps://faculty.medicine.hofstra.edu/13732-amos-grunebaum/publications *SWW S23 Theme Song & Artwork: Thank you so much to Emily Wolfe for covering Glad Rag's original song, U Think U for us this season!Hear more from Emily Wolfe:On SpotifyOn Apple Musichttps://www.emilywolfemusic.com/instagram.com/emilywolfemusicGlad Rags: https://www.gladragsmusic.com/ The S23 cover art is by the Amazing Sara StewartFollow Something Was Wrong:Website: somethingwaswrong.com IG: instagram.com/somethingwaswrongpodcastTikTok: tiktok.com/@somethingwaswrongpodcast Follow Tiffany Reese:Website: tiffanyreese.me IG: instagram.com/lookiebooSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of The Financial Guys Podcast, Mike Sperrazza and Mike Lomas take aim at the Biden administration's cover-ups—starting with the President's hidden cancer diagnosis. The Mikes break down how bloated government, zero accountability, and taxpayer-funded corruption are gutting the country from the inside. From the true cost of illegal immigration and out-of-control education budgets to the myth of WNBA wage gaps and the Epstein list that still hasn't surfaced, this episode is packed with hard-hitting truths and unapologetic conservative fire.(00:05:47) Managing Government Operations for Optimal Efficiency(00:11:20) Proactive Steps for Timely Legal Accountability(00:17:12) Revitalizing Economically Challenged Areas Through Tax Incentives(00:21:55) Crime-Related Insurance Premium Burden on Businesses(00:23:58) Repeat Offenders and the Cashless Bail(00:28:41) Efficiency and Oversight in School District Budgets.(00:32:00) Disparities in School Spending Allocation(00:37:20) Deportation and Trafficking in Border Security(00:40:25) Safety Measures in Immigration Screening Process(00:43:10) Wealth Creation Through Hard Work and Responsibility(00:46:19) Gender Disparity in Professional Sports Revenue

Kendrick Fulton talks about his 400-month sentence for drug dealing, how he navigated life in federal prison, and what kept him going. #LongPrisonSentence #FederalPrison #TrueCrime #DrugTrafficking #JusticeSystem #CrimeAndPunishment #HardTime #exconvict Thank you to LUCY & DRAFT KINGS for sponsoring today's episode: Lucy: Let's level up your nicotine routine with Lucy.  Go to HTTP://LUCY.CO/IANBICK and use promo code (IANBICK) to get 20% off your first order. Lucy has a 30-day refund policy if you change your mind.  Draft Kings: New players can get FIVE HUNDRED CASINO SPINS ON A FEATURED GAME! Just sign up with code IANBICK and wager a minimum of five dollars to receive FIVE HUNDRED CASINO SPINS ON A FEATURED GAME.Get 35% off polarized glasses at shadyrays.com - code LOCKEDIN Connect with Kendrick Fulton: Instagram: https://www.instagram.com/lifeinthefeds?igsh=MXB4ZDJwMjdtbDZoZw== Hosted, Executive Produced & Edited By Ian Bick: https://www.instagram.com/ian_bick/?hl=en https://ianbick.com/ Presented by Tyson 2.0 & Wooooo Energy: https://tyson20.com/ https://woooooenergy.com/ Buy Merch: https://convictclothing.net/collections/convict-clothing-x-ian-bick Timestamps: 00:00:00 Kendrick's Journey Back to Society 00:05:20 Childhood Lessons on Work and Values 00:11:00 Navigating Probation and College Life 00:16:34 Why College Isn't for Everyone 00:22:10 The Misrepresentation of Small Operations by the Government 00:27:40 Federal Drug Investigation: Conviction Strategies 00:33:19 Escaping to Denver: A New Life in Colorado 00:39:18 Prison Transport Journey and Challenges 00:44:41 Turning Yourself In: The Emotional Journey 00:50:18 The Meaning of Forgiveness 00:55:53 Lessons from the Streets to Legal Business 01:00:54 Defying the Odds: Success Stories of Children with Incarcerated Parents 01:06:09 Disparities in Sentencing for Drug Offenses 01:14:23 Early Release from Prison Due to COVID-19 Pandemic 01:17:18 Life After Imprisonment: New Beginnings in Austin 01:22:57 Transition and Trying Viral Chicken Sandwiches 01:28:31 Future Podcast Plans with Kendrick Powered by: Just Media House : https://www.justmediahouse.com/ Creative direction, design, assets, support by FWRD: https://www.fwrd.co Learn more about your ad choices. Visit megaphone.fm/adchoices

The May 2025 recall features four previously posted episodes on myasthenia gravis. The first episode has Dr. Fredrik Piehl discussing rituximab for new-onset generalized MG. In the second episode, Dr. Vera Bril explores the potential use of immunoglobulin as a corticosteroid-sparing agent in MG patients. The third episode features Dr. Ali A. Habib discussing trends in hospital admissions and in-hospital mortality for adult MG patients. The series concludes with Dr. Jennifer Morganroth addressing the increase in thymectomy procedures post-MGTX trial, disparities in access to these surgeries among different demographic groups, and the rise of minimally invasive surgical techniques. Podcast links: Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis  Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis Hospitalizations and Mortality from MG Hospitalizations and Mortality From Myasthenia Gravis Trends and Disparities in the Utilization of Thymectomy for MG in the US Article links: Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis Hospitalizations and Mortality From Myasthenia Gravis Trends and Disparities in the Utilization of Thymectomy for Myasthenia Gravis in the United States Disclosures can be found at Neurology.org.